JP2012512145A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512145A5
JP2012512145A5 JP2011540128A JP2011540128A JP2012512145A5 JP 2012512145 A5 JP2012512145 A5 JP 2012512145A5 JP 2011540128 A JP2011540128 A JP 2011540128A JP 2011540128 A JP2011540128 A JP 2011540128A JP 2012512145 A5 JP2012512145 A5 JP 2012512145A5
Authority
JP
Japan
Prior art keywords
benzimidazol
trifluoro
dihydro
phenyl
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011540128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/067007 external-priority patent/WO2010079045A2/en
Publication of JP2012512145A publication Critical patent/JP2012512145A/ja
Publication of JP2012512145A5 publication Critical patent/JP2012512145A5/ja
Pending legal-status Critical Current

Links

JP2011540128A 2008-12-15 2009-12-14 フリバンセリンの結晶性の塩形態 Pending JP2012512145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08171699 2008-12-15
EP08171699.5 2008-12-15
PCT/EP2009/067007 WO2010079045A2 (en) 2008-12-15 2009-12-14 New salts

Publications (2)

Publication Number Publication Date
JP2012512145A JP2012512145A (ja) 2012-05-31
JP2012512145A5 true JP2012512145A5 (cg-RX-API-DMAC7.html) 2013-02-07

Family

ID=42115616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540128A Pending JP2012512145A (ja) 2008-12-15 2009-12-14 フリバンセリンの結晶性の塩形態

Country Status (5)

Country Link
US (2) US20120322810A9 (cg-RX-API-DMAC7.html)
EP (1) EP2376457A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012512145A (cg-RX-API-DMAC7.html)
CA (1) CA2686480A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010079045A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
EP2097389B1 (en) * 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
US11492343B2 (en) 2016-01-31 2022-11-08 Xiaoming Meng Polymorph of flibanserin and preparation method thereof and use of same
WO2017142002A1 (ja) * 2016-02-17 2017-08-24 大正製薬株式会社 Ｃ－４"位置換マクロライド化合物フリー体及び塩の結晶形並びにそれらの製造方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
DK251079A (da) 1978-06-20 1979-12-21 Synthelabo Fremgangsmaade til fremstilling af phenylpiperazinderivater
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
NL8601494A (nl) 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
HUT68769A (en) 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US5883094A (en) 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
ATE271379T1 (de) 1996-11-06 2004-08-15 Wockhardt Europ Ltd System zur verzögerten freisetzung säurelabiler substanzen
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
ES2267627T3 (es) 2001-05-11 2007-03-16 Jurgen K. Dr. Beck Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal.
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP1518858A1 (en) * 2001-08-02 2005-03-30 BIDACHEM S.p.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
JP2007533686A (ja) 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性的障害ｉｉ治療用の新規医薬組成物
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
JP2008511569A (ja) 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
JP2008540356A (ja) 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
US20060258640A1 (en) 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
WO2008019996A2 (en) * 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
MX2009002031A (es) 2006-08-25 2009-03-06 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo.
EP2097389B1 (en) 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
JP2010522714A (ja) 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物

Similar Documents

Publication Publication Date Title
JP2012512145A5 (cg-RX-API-DMAC7.html)
JP6689942B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
CN102617513B (zh) 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
JP5603244B2 (ja) Ｓｅｒｔ、５−ｈｔ３および５−ｈｔ１ａの組み合わせた活性を有する化合物の治療的使用
US10272031B2 (en) Memantine pamoate, method of preparation and use thereof
TWI343381B (en) Process for the production of benzopyran-2-ol derivatives
JP2010189441A (ja) ヒスタミンｈ３−受容体リガンドとしての非イミダゾールアルキルアミンと、その治療への応用
HRP20110412T1 (hr) Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
TWI751998B (zh) 結晶型化合物
EP2909191A1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
JP2010519300A5 (cg-RX-API-DMAC7.html)
CN1914191A (zh) 4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－(4－吡啶－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺的盐形式
TWI441630B (zh) 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物
CN110831930A (zh) 杂环亚基乙酰胺衍生物的晶体
JP2011511818A5 (cg-RX-API-DMAC7.html)
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
TWI731153B (zh) 用於治療神經性起立性低血壓之化合物
JP2009513604A5 (cg-RX-API-DMAC7.html)
JP2018522945A (ja) ビラスチンの結晶形態及びそれらの調製方法
JP2010540470A5 (cg-RX-API-DMAC7.html)
CN101139341B (zh) 具有止痛活性的吲唑酰胺类
JP5600253B2 (ja) 情動障害の治療のための［２−（６−フルオロ−１ｈ−インドール−３−イルスルファニル）ベンジル］メチルアミン
KR101404836B1 (ko) 아고멜라틴의 공결정 및 그의 제조방법
TWI267510B (en) Pharmaceutical salts of reboxetine
TW201124139A (en) Solid forms of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-n, n-diethylbenzamide, compositions thereof, and uses therewith